The Innova-Sinopharma PR says Innova Biomedical has a base in Singapore -

Pasaca Capital, Inc. with its portfolio company Innova Medical Group Establish Joint Venture with Sinopharm Group to Improve Access to COVID-19 Vaccines
- Dr. Robert Redfield, Chief Scientific Advisor to Pasaca and Former US CDC Commissioner and Dr. Yichen Lu will lead the vaccine effort for Pasaca and Innova

- Sinopharm's China National Biotech Group (CNBG) produces the most widely used COVID-19 vaccines globally and is ramping up production capacity to 7 billion doses annually by the end of 2021

- Sino-Innovax Biotech Pte Ltd is a 49:51 partnership between Innova Bio-Medical Pte Ltd (Singapore), a subsidiary wholly owned by Pasaca Capital Inc and Sinopharm Biotech Co Ltd (Hong Kong), a wholly owned subsidiary of CNBG

- JV will expand access to WHO approved, highly effective COVID-19 vaccines, especially to those in less developed areas where cold supply chain is not available

NEWS PROVIDED BY

Pasaca Capital, Inc.
Nov 11, 2021, 15:14 ET
https://www.prnewswire.com/news-releases/pasa...22575.html